Researchers have developed an innovative microneedle patch using stevioside to significantly boost minoxidil absorption for male pattern baldness, demonstrating 18 times greater absorption and rapid hair regrowth in mice compared to traditional application. This novel delivery system, utilizing dissolvable, less irritating Stevia-based needles, promises enhanced drug penetration and a simplified treatment regimen, potentially revolutionizing the efficacy and patient experience of a widely used hair loss treatment and creating new commercial opportunities for pharmaceutical firms.
While the topical application of minoxidil is one of the most effective and popular ways to combat male pattern baldness, it is poorly absorbed by the skin. Looking to improve its efficacy, researchers have turned to an unlikely but very sweet ally. Male pattern baldness (MPB), also known as androgenetic alopecia (AGA), is an inherited condition in which men gradually lose their hair according to a specific pattern that ultimately leaves them with only a little bit of hair on the sides and back of their heads. It is responsible for more than 95% of hair loss in men. Since 1988, minoxidil – a drug originally developed to fight high blood pressure – has been used by men to combat the condition to one degree or another. However, minoxidil is applied directly to the scalp and, paradoxically, is poorly absorbed by the skin. Now researchers from Australia and China believe they have come up with a way to boost the drug's absorption and therefore its potency. They developed a patch containing minoxidil and a set of microneedles made from stevioside, a natural sweetener derived from the Stevia plant. After tuning the concentrations of the sweetener contained in the needles, the patches were applied to mice that had been genetically altered to exhibit MPB. The researchers found that the mice given the Stevia patch had 18 times better absorption of minoxidil than a control group. The treated mice also had hair coverage of 67.5% in previously bald areas after just 35 days. That's significantly better than the current efficacy of the drug, which typically takes three to six months to produce new hair growth in humans. Unlike other microneedle patches that had been tried in the past, the Stevia-based needles dissolved after application and were minimally metabolized, meaning that most of the sweetener was excreted. Their dissolvability led them to be less irritating than patches that had been previously tested using metal-based needles. "The microneedle patch simplifies the treatment regimen by providing a more convenient, long-acting option that ensures controlled and prolonged drug release directly to the targeted area," write the researchers in their study, which has been published in the journal Advanced Healthcare Materials. "This method not only enhances drug penetration into skin but also eliminates other issues associated with traditional topical formulations, such as slow onset of action and/or inaccurate dosing. By combining the advantages of microneedling with the therapeutic benefits of minoxidil, and utilizing Stevia's unique properties, this approach holds significant potential for improving clinical outcomes in the treatment of AGA." Source: Wiley via EurekAlert Researchers have developed a novel microneedle patch utilizing stevioside to significantly enhance minoxidil absorption for male pattern baldness (MPB). Preclinical studies in genetically altered mice demonstrated an 18-fold increase in minoxidil absorption compared to controls, leading to 67.5% hair coverage in previously bald areas within just 35 days. This represents a substantial improvement over current topical minoxidil efficacy, which typically requires three to six months for initial human hair growth. The Stevia-based microneedle patches offer several key advantages: they are dissolvable, less irritating than previous metal-based alternatives, and simplify the treatment regimen. This advanced delivery system ensures controlled and prolonged drug release directly to the targeted area, improving drug penetration and eliminating issues like slow onset or inaccurate dosing associated with traditional topical applications. Researchers characterize this approach as holding "significant potential for improving clinical outcomes" for androgenetic alopecia (AGA). While no specific company is named, this innovation could reshape the hair loss treatment market by offering a superior patient experience and enhanced efficacy. It presents a compelling case for investment in firms specializing in advanced drug delivery technologies or dermatology assets, potentially leading to licensing opportunities or strategic acquisitions within the healthcare and biotech sectors. The moderately positive sentiment and moderate market impact underscore its early-stage promise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.70
